Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas (Q35023441)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas |
scientific article |
Statements
1 reference
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas (English)
1 reference
Kelly Hunt
1 reference
Laura J Esserman
1 reference
Vera J Suman
1 reference
Gildy V Babiera
1 reference
Matthew J Ellis
1 reference
Jeremy Hoog
1 reference
Li Lin
1 reference
Jacqueline Snider
1 reference
Aleix Prat
1 reference
Joel S Parker
1 reference
Jingqin Luo
1 reference
Katherine DeSchryver
1 reference
D Craig Allred
1 reference
Gary W Unzeitig
1 reference
Julie Margenthaler
1 reference
P Kelly Marcom
1 reference
Joseph M Guenther
1 reference
Mark A Watson
1 reference
Marilyn Leitch
1 reference
John A Olson
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference